Amgen, Inc. (AMGN) Holdings Decreased by Mutual of America Capital Management LLC
Mutual of America Capital Management LLC cut its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 88,186 shares of the medical research company’s stock after selling 1,471 shares during the period. Mutual of America Capital Management LLC’s holdings in Amgen were worth $16,442,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. RNC Capital Management LLC boosted its stake in shares of Amgen by 10.0% in the first quarter. RNC Capital Management LLC now owns 129,993 shares of the medical research company’s stock valued at $21,328,000 after purchasing an additional 11,822 shares during the period. Meadow Creek Investment Management LLC boosted its stake in shares of Amgen by 22.4% in the first quarter. Meadow Creek Investment Management LLC now owns 25,200 shares of the medical research company’s stock valued at $4,135,000 after purchasing an additional 4,608 shares during the period. Affinity Investment Advisors LLC boosted its stake in shares of Amgen by 1.0% in the first quarter. Affinity Investment Advisors LLC now owns 86,970 shares of the medical research company’s stock valued at $14,269,000 after purchasing an additional 884 shares during the period. Main Street Research LLC boosted its stake in shares of Amgen by 1.0% in the first quarter. Main Street Research LLC now owns 68,468 shares of the medical research company’s stock valued at $11,233,000 after purchasing an additional 692 shares during the period. Finally, Morningstar Investment Services LLC boosted its stake in shares of Amgen by 283.8% in the first quarter. Morningstar Investment Services LLC now owns 497,503 shares of the medical research company’s stock valued at $81,625,000 after purchasing an additional 367,894 shares during the period. Institutional investors and hedge funds own 78.62% of the company’s stock.
Amgen, Inc. (AMGN) opened at $177.04 on Monday. Amgen, Inc. has a 12 month low of $145.12 and a 12 month high of $191.10. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05. The stock has a market cap of $128,515.28, a P/E ratio of 14.07, a P/E/G ratio of 2.57 and a beta of 1.36.
Amgen announced that its board has authorized a share repurchase program on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 dividend on an annualized basis and a yield of 2.98%. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is presently 41.63%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $171.58, for a total transaction of $261,659.50. Following the sale, the executive vice president now owns 57,631 shares of the company’s stock, valued at $9,888,326.98. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,575 shares of company stock worth $1,509,339. 0.19% of the stock is owned by corporate insiders.
Several research firms have recently commented on AMGN. Goldman Sachs Group lowered shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday. Oppenheimer set a $205.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday, December 12th. BidaskClub raised shares of Amgen from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 2nd. Cann reissued a “buy” rating and issued a $205.00 price objective on shares of Amgen in a research note on Thursday, November 30th. Finally, Argus lowered shares of Amgen from a “buy” rating to a “hold” rating and raised their price objective for the company from $175.22 to $195.00 in a research note on Wednesday, November 1st. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $190.22.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/amgen-inc-amgn-holdings-decreased-by-mutual-of-america-capital-management-llc/1770560.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.